<?xml version='1.0' encoding='utf-8'?>
<document id="25700638"><sentence text="Effect of proton-pump inhibitors on the risk of lower gastrointestinal bleeding associated with NSAIDs, aspirin, clopidogrel, and warfarin."><entity charOffset="104-111" id="DDI-PubMed.25700638.s1.e0" text="aspirin" /><entity charOffset="113-124" id="DDI-PubMed.25700638.s1.e1" text="clopidogrel" /><entity charOffset="130-138" id="DDI-PubMed.25700638.s1.e2" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.25700638.s1.e0" e2="DDI-PubMed.25700638.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25700638.s1.e0" e2="DDI-PubMed.25700638.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25700638.s1.e0" e2="DDI-PubMed.25700638.s1.e2" /><pair ddi="false" e1="DDI-PubMed.25700638.s1.e1" e2="DDI-PubMed.25700638.s1.e1" /><pair ddi="false" e1="DDI-PubMed.25700638.s1.e1" e2="DDI-PubMed.25700638.s1.e2" /></sentence><sentence text="We investigated the effects of proton-pump inhibitors (PPIs) on lower gastrointestinal bleeding (LGIB) and of their interactions with nonsteroidal anti-inflammatory drugs (NSAIDs), low-dose aspirin, clopidogrel, and warfarin on LGIB risk"><entity charOffset="190-197" id="DDI-PubMed.25700638.s2.e0" text="aspirin" /><entity charOffset="199-210" id="DDI-PubMed.25700638.s2.e1" text="clopidogrel" /><entity charOffset="216-224" id="DDI-PubMed.25700638.s2.e2" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.25700638.s2.e0" e2="DDI-PubMed.25700638.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25700638.s2.e0" e2="DDI-PubMed.25700638.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25700638.s2.e0" e2="DDI-PubMed.25700638.s2.e2" /><pair ddi="false" e1="DDI-PubMed.25700638.s2.e1" e2="DDI-PubMed.25700638.s2.e1" /><pair ddi="false" e1="DDI-PubMed.25700638.s2.e1" e2="DDI-PubMed.25700638.s2.e2" /></sentence><sentence text="" /><sentence text="We prospectively studied 355 patients emergently hospitalized for LGIB and 8,221 nonbleeding patients" /><sentence text=" All patients underwent colonoscopy" /><sentence text=" Smoking, alcohol drinking, drug exposure, and the Charlson comorbidity index score were assessed before colonoscopy"><entity charOffset="10-17" id="DDI-PubMed.25700638.s6.e0" text="alcohol" /></sentence><sentence text=" Adjusted odds ratios (AOR) of LGIB were estimated" /><sentence text="" /><sentence text="LGIB was significantly associated with older age, higher comorbidity index, and NSAID, aspirin, clopidogrel, or warfarin use"><entity charOffset="87-94" id="DDI-PubMed.25700638.s9.e0" text="aspirin" /><entity charOffset="96-107" id="DDI-PubMed.25700638.s9.e1" text="clopidogrel" /><entity charOffset="112-120" id="DDI-PubMed.25700638.s9.e2" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.25700638.s9.e0" e2="DDI-PubMed.25700638.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25700638.s9.e0" e2="DDI-PubMed.25700638.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25700638.s9.e0" e2="DDI-PubMed.25700638.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25700638.s9.e1" e2="DDI-PubMed.25700638.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25700638.s9.e1" e2="DDI-PubMed.25700638.s9.e2" /></sentence><sentence text=" PPI use was significantly associated with older age, male sex, being a current alcohol drinker, higher comorbidity index, and NSAID, aspirin, clopidogrel, warfarin, acetaminophen, or corticosteroid use"><entity charOffset="80-87" id="DDI-PubMed.25700638.s10.e0" text="alcohol" /><entity charOffset="134-141" id="DDI-PubMed.25700638.s10.e1" text="aspirin" /><entity charOffset="143-154" id="DDI-PubMed.25700638.s10.e2" text="clopidogrel" /><entity charOffset="156-164" id="DDI-PubMed.25700638.s10.e3" text="warfarin" /><entity charOffset="166-179" id="DDI-PubMed.25700638.s10.e4" text="acetaminophen" /><entity charOffset="184-198" id="DDI-PubMed.25700638.s10.e5" text="corticosteroid" /><pair ddi="false" e1="DDI-PubMed.25700638.s10.e0" e2="DDI-PubMed.25700638.s10.e0" /><pair ddi="false" e1="DDI-PubMed.25700638.s10.e0" e2="DDI-PubMed.25700638.s10.e1" /><pair ddi="false" e1="DDI-PubMed.25700638.s10.e0" e2="DDI-PubMed.25700638.s10.e2" /><pair ddi="false" e1="DDI-PubMed.25700638.s10.e0" e2="DDI-PubMed.25700638.s10.e3" /><pair ddi="false" e1="DDI-PubMed.25700638.s10.e0" e2="DDI-PubMed.25700638.s10.e4" /><pair ddi="false" e1="DDI-PubMed.25700638.s10.e0" e2="DDI-PubMed.25700638.s10.e5" /><pair ddi="false" e1="DDI-PubMed.25700638.s10.e1" e2="DDI-PubMed.25700638.s10.e1" /><pair ddi="false" e1="DDI-PubMed.25700638.s10.e1" e2="DDI-PubMed.25700638.s10.e2" /><pair ddi="false" e1="DDI-PubMed.25700638.s10.e1" e2="DDI-PubMed.25700638.s10.e3" /><pair ddi="false" e1="DDI-PubMed.25700638.s10.e1" e2="DDI-PubMed.25700638.s10.e4" /><pair ddi="false" e1="DDI-PubMed.25700638.s10.e1" e2="DDI-PubMed.25700638.s10.e5" /><pair ddi="false" e1="DDI-PubMed.25700638.s10.e2" e2="DDI-PubMed.25700638.s10.e2" /><pair ddi="false" e1="DDI-PubMed.25700638.s10.e2" e2="DDI-PubMed.25700638.s10.e3" /><pair ddi="false" e1="DDI-PubMed.25700638.s10.e2" e2="DDI-PubMed.25700638.s10.e4" /><pair ddi="false" e1="DDI-PubMed.25700638.s10.e2" e2="DDI-PubMed.25700638.s10.e5" /><pair ddi="false" e1="DDI-PubMed.25700638.s10.e3" e2="DDI-PubMed.25700638.s10.e3" /><pair ddi="false" e1="DDI-PubMed.25700638.s10.e3" e2="DDI-PubMed.25700638.s10.e4" /><pair ddi="false" e1="DDI-PubMed.25700638.s10.e3" e2="DDI-PubMed.25700638.s10.e5" /><pair ddi="false" e1="DDI-PubMed.25700638.s10.e4" e2="DDI-PubMed.25700638.s10.e4" /><pair ddi="false" e1="DDI-PubMed.25700638.s10.e4" e2="DDI-PubMed.25700638.s10.e5" /></sentence><sentence text=" Multivariate analysis adjusted by the confounding factors revealed LGIB was not significantly associated with PPI use (AOR 0" /><sentence text="87; 95 % confidence interval 0" /><sentence text="68-1" /><sentence text="13; p = 0" /><sentence text="311), or specifically with omeprazole (AOR 1"><entity charOffset="27-37" id="DDI-PubMed.25700638.s15.e0" text="omeprazole" /></sentence><sentence text="18; p = 0" /><sentence text="408), esomeprazole (AOR 0"><entity charOffset="6-18" id="DDI-PubMed.25700638.s17.e0" text="esomeprazole" /><entity charOffset="20-23" id="DDI-PubMed.25700638.s17.e1" text="AOR" /><pair ddi="false" e1="DDI-PubMed.25700638.s17.e0" e2="DDI-PubMed.25700638.s17.e0" /><pair ddi="false" e1="DDI-PubMed.25700638.s17.e0" e2="DDI-PubMed.25700638.s17.e1" /></sentence><sentence text="76; p = 0" /><sentence text="432), lansoprazole (AOR 0"><entity charOffset="6-18" id="DDI-PubMed.25700638.s19.e0" text="lansoprazole" /><entity charOffset="20-23" id="DDI-PubMed.25700638.s19.e1" text="AOR" /><pair ddi="false" e1="DDI-PubMed.25700638.s19.e0" e2="DDI-PubMed.25700638.s19.e0" /><pair ddi="false" e1="DDI-PubMed.25700638.s19.e0" e2="DDI-PubMed.25700638.s19.e1" /></sentence><sentence text="93; p = 0" /><sentence text="669), or rabeprazole (AOR 0"><entity charOffset="9-20" id="DDI-PubMed.25700638.s21.e0" text="rabeprazole" /><entity charOffset="22-25" id="DDI-PubMed.25700638.s21.e1" text="AOR" /><pair ddi="false" e1="DDI-PubMed.25700638.s21.e0" e2="DDI-PubMed.25700638.s21.e0" /><pair ddi="false" e1="DDI-PubMed.25700638.s21.e0" e2="DDI-PubMed.25700638.s21.e1" /></sentence><sentence text="63; p = 0" /><sentence text="140)" /><sentence text=" In the interaction model, no significant interactions were observed between PPIs and NSAIDs (AOR 1"><entity charOffset="94-96" id="DDI-PubMed.25700638.s24.e0" text="AOR" /></sentence><sentence text="40; p = 0" /><sentence text="293), aspirin (AOR 1"><entity charOffset="6-13" id="DDI-PubMed.25700638.s26.e0" text="aspirin" /><entity charOffset="15-21" id="DDI-PubMed.25700638.s26.e1" text="AOR" /><pair ddi="false" e1="DDI-PubMed.25700638.s26.e0" e2="DDI-PubMed.25700638.s26.e0" /><pair ddi="false" e1="DDI-PubMed.25700638.s26.e0" e2="DDI-PubMed.25700638.s26.e1" /></sentence><sentence text="09; p = 0" /><sentence text="767), clopidogrel (AOR 0"><entity charOffset="6-17" id="DDI-PubMed.25700638.s28.e0" text="clopidogrel" /><entity charOffset="19-29" id="DDI-PubMed.25700638.s28.e1" text="AOR" /><pair ddi="false" e1="DDI-PubMed.25700638.s28.e0" e2="DDI-PubMed.25700638.s28.e0" /><pair ddi="false" e1="DDI-PubMed.25700638.s28.e0" e2="DDI-PubMed.25700638.s28.e1" /></sentence><sentence text="99, p = 0" /><sentence text="985), or warfarin (AOR 1"><entity charOffset="19-21" id="DDI-PubMed.25700638.s30.e0" text="AOR" /></sentence><sentence text="52; p = 0" /><sentence text="398)" /><sentence text="" /><sentence text="This large case-control study demonstrated that PPI use did not lead to an increased risk of LGIB, regardless of the type of PPI used" /><sentence text=" Further, LGIB risk was not affected by PPI use, irrespective of concomitant therapy with NSAIDs, low-dose aspirin, clopidogrel, or warfarin"><entity charOffset="107-114" id="DDI-PubMed.25700638.s35.e0" text="aspirin" /><entity charOffset="116-127" id="DDI-PubMed.25700638.s35.e1" text="clopidogrel" /><entity charOffset="132-140" id="DDI-PubMed.25700638.s35.e2" text="warfarin" /><pair ddi="false" e1="DDI-PubMed.25700638.s35.e0" e2="DDI-PubMed.25700638.s35.e0" /><pair ddi="false" e1="DDI-PubMed.25700638.s35.e0" e2="DDI-PubMed.25700638.s35.e1" /><pair ddi="false" e1="DDI-PubMed.25700638.s35.e0" e2="DDI-PubMed.25700638.s35.e2" /><pair ddi="false" e1="DDI-PubMed.25700638.s35.e1" e2="DDI-PubMed.25700638.s35.e1" /><pair ddi="false" e1="DDI-PubMed.25700638.s35.e1" e2="DDI-PubMed.25700638.s35.e2" /></sentence><sentence text="" /></document>